DOI:
10.1055/s-00033990
TH Open
LinksClose Window
References
Ezekowitz MD, Cappato R, Klein AL. , et al.
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Am Heart J 2014;
167 (05) 646-652
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.